Toxicology – Toxins Causing Cyanosis


Ergotamine
Ergot compounds can lead to acrocyanosis due to intense vasoconstriction, resembling a secondary Raynaud phenomenon affecting peripheral circulation.


Phenazopyridine
This urinary tract analgesic can induce methemoglobinemia, impairing oxygen delivery and resulting in cyanosis.


Aniline
Aniline, a chemical used in the production of dyes and polyurethane, can cause both methemoglobinemia and hemolytic anemia, contributing to cyanotic discoloration.


Dapsone
Dapsone, used in the treatment of leprosy and for Pneumocystis jirovecii pneumonia prophylaxis, is a well-known cause of methemoglobinemia.


Nitrates
Nitrates, sometimes present in contaminated well water, can induce methemoglobinemia, particularly in infants.


Nitrites
Nitrites are used therapeutically to induce methemoglobinemia in cyanide poisoning but may also be abused recreationally for their vasodilatory effects, leading to cyanosis.


Asphyxia
Conditions causing hypoxemia or impaired oxygen delivery increase levels of deoxygenated hemoglobin, resulting in cyanosis.


Treatment
Methylene blue is the treatment of choice for methemoglobinemia. It acts as a reducing agent, converting methemoglobin back to functional hemoglobin, and is typically administered at a dose of 1–2 mg/kg intravenously over 5 minutes.

​

Toxicology – Non-Anion Gap Metabolic Acidosis (HARD UP)


Hyperalimentation (TPN)
Total parenteral nutrition with excessive chloride content can result in hyperchloremic metabolic acidosis. Management involves reducing chloride and increasing acetate in the formulation. Regular monitoring with daily basic metabolic panels is important in these patients.


Acetazolamide
Acetazolamide inhibits carbonic anhydrase in the proximal tubule, leading to increased urinary bicarbonate loss and a non-anion gap metabolic acidosis. Patients may experience paresthesias in the extremities and a metallic taste.


Renal Tubular Acidosis (RTA)
Renal tubular dysfunction impairs acid and ammonia excretion, resulting in hyperchloremic metabolic acidosis. It is classified into Type I (distal, hypokalemic), Type II (proximal, hypokalemic), and Type IV (hyperkalemic). Type III is no longer recognized as a separate entity.


Diarrhea
Loss of bicarbonate through the gastrointestinal tract leads to non-anion gap metabolic acidosis. Treatment includes intravenous fluids and bicarbonate replacement.


Ureteroenteric Fistula
This condition can cause metabolic acidosis through several mechanisms: reabsorption of ammonium chloride from urine, exchange of chloride for bicarbonate in the bowel, and renal tubular impairment. Risk increases with prolonged urine exposure to bowel mucosa and greater surface area involvement.


Pancreaticoduodenal Fistula
Similar to diarrhea, this condition leads to bicarbonate loss and subsequent non-anion gap metabolic acidosis. Management focuses on fluid resuscitation and correction of electrolyte imbalances.

​

Infectious disease and microbiology – Mycotic aneurysms
Mycotic aneurysms are infected aneurysms of blood vessels that arise as part of an infectious process, most commonly infective endocarditis (IE). Despite the name, “mycotic” refers to the fungus-like shape of the aneurysm, not the cause, which is usually bacterial.

These aneurysms may be intracranial or extracranial, and they can also occur due to infection of a preexisting aneurysm or arterial wall (microbial arteritis).

Epidemiologically, about 2–4% of patients with infective endocarditis develop intracranial mycotic aneurysms, although the true incidence is likely underestimated due to asymptomatic cases. The prevalence in the general population is unknown but has decreased in the antibiotic era.

Major risk factors include:

• Infective endocarditis
• Intravenous drug use
• Arterial trauma
• Contiguous infections near blood vessels
• Immunosuppression and advanced age

The pathophysiology involves infection and weakening of the arterial wall through several mechanisms:

• Septic emboli from cardiac vegetations lodging in vessels
• Bacteremic seeding of damaged arterial intima
• Direct spread from nearby infections
• Direct inoculation from trauma or procedures

The most common causative organism is Staphylococcus aureus (up to 70%), followed by Salmonella species. Other pathogens include streptococci, gram-negative bacteria, Mycobacterium tuberculosis, and fungi such as Candida and Aspergillus.

Clinically, many patients are asymptomatic until complications occur.
Symptoms depend on location:

• Intracranial aneurysms: headache, fever, stroke-like symptoms, seizures
• Aortic aneurysms: abdominal or back pain, fever
• Rupture: sudden deterioration, bleeding, shock

Physical findings may include neurologic deficits, meningeal signs, abdominal tenderness, or signs of hemorrhage, depending on the site.

Diagnosis relies on a combination of laboratory tests and imaging.

• Blood cultures are positive in 50–85% of cases
• Elevated white blood cell count and anemia are common
• Conventional angiography is the gold standard
• CT, MRI, and Doppler ultrasound help localize and assess the aneurysm

Pathologically, there is destruction of the arterial wall, inflammation, and eventual dilation with risk of rupture, especially at vessel branching points.

Treatment involves prolonged intravenous antibiotics (at least 6–8 weeks) tailored to the identified organism.
Some patients, especially those with intracranial aneurysms, may improve with antibiotics alone.

Surgical or endovascular intervention is required in cases of:

• Rupture or bleeding
• Enlarging aneurysm despite therapy
• High-risk anatomical locations

Close monitoring is essential, particularly during the first weeks of treatment, as rupture risk is highest early but may still occur months later.

The prognosis is serious, with mortality depending on rupture status:

• ~30% mortality if aneurysm is intact
• Up to 80% mortality if rupture occurs

Complications include:

• Hemorrhage (e.g., subarachnoid hemorrhage)
• Embolization
• Vascular insufficiency
• Shock and death
• ​

Early recognition and treatment of underlying infections, especially infective endocarditis, are critical to improving outcomes.

​Infectious disease and microbiology – Mucormycosis


Mucormycosis is a life-threatening opportunistic fungal infection characterized by vascular invasion, thrombosis, and extensive tissue necrosis. It primarily affects immunocompromised individuals, particularly those with uncontrolled diabetes or hematologic malignancies.


The disease is relatively rare, with an estimated incidence of 1.7 cases per million people annually in the United States, but it carries a very high mortality rate. It occurs worldwide and is increasingly recognized in patients receiving antifungal prophylaxis that does not cover Mucorales (e.g., voriconazole).


Major risk factors include uncontrolled diabetes mellitus (especially with ketoacidosis), hematologic malignancies, organ transplantation, prolonged neutropenia, chronic steroid use, deferoxamine therapy, burns, trauma, and intravenous drug use. HIV infection and malnutrition also predispose to disease. Nosocomial outbreaks have been reported, particularly due to contaminated dressings.


Infection occurs through inhalation, ingestion, or direct inoculation of fungal spores. Once inside the host, Mucorales organisms invade blood vessels, leading to thrombosis, infarction, and necrosis, with rapid spread to adjacent tissues and possible hematogenous dissemination.


The most common causative organisms are molds from the order Mucorales, including Rhizopus, Mucor, Rhizomucor, Absidia, Cunninghamella, and Saksenaea. These fungi are ubiquitous in the environment, especially in soil and decaying organic matter.


Clinical presentation varies depending on the site of infection but is typically rapidly progressive and severe.


Rhinocerebral (craniofacial) mucormycosis, most common in diabetics, begins in the sinuses and spreads to the orbit and brain. Patients may present with facial pain, nasal congestion, black necrotic lesions on the palate or nasal mucosa, orbital swelling, vision loss, and altered mental status.


Pulmonary mucormycosis occurs mainly in neutropenic patients and presents with fever, progressive lung infiltrates, and poor response to antibiotics.


Gastrointestinal mucormycosis is more common in malnourished children and presents with abdominal pain, bleeding, or perforation.


Cutaneous mucormycosis occurs after trauma or burns and presents with necrotic ulcers, eschars, and tissue destruction.


Disseminated disease may involve the brain, liver, spleen, or heart and carries a very poor prognosis.


Diagnosis relies on early clinical suspicion and histopathological confirmation. Microscopy shows broad, nonseptate, irregularly branching hyphae. Culture may be performed from tissue samples, and imaging (CT or MRI) helps assess the extent of disease. Unlike other fungal infections, β-D-glucan tests are not useful.


Treatment requires urgent, aggressive management.


First-line therapy includes intravenous amphotericin B (liposomal formulation preferred due to lower toxicity).


Second-line or salvage therapy includes posaconazole, sometimes used in combination regimens.


Equally important are reversal of underlying risk factors (e.g., control of diabetes, reduction of immunosuppression) and prompt surgical debridement of necrotic tissue, which is often lifesaving.


Additional supportive therapies may include granulocyte transfusions, growth factors, hyperbaric oxygen therapy, and iron chelation strategies in selected cases.


The prognosis remains poor, especially if diagnosis is delayed. Untreated rhinocerebral disease is almost universally fatal within days, while even with treatment, survival in diabetic patients is approximately 50%. Outcomes are worse in immunocompromised individuals and in disseminated disease.


Complications include vascular thrombosis, brain abscesses, pulmonary dissemination, bowel infarction, hemorrhage, and widespread tissue destruction, often leading to death if not rapidly treated.

Infectious Disease and Microbiology - Acute Meningitis
Acute meningitis is a rapidly developing inflammation of the meninges that typically evolves over hours to days. It may resolve spontaneously in viral cases or require urgent treatment when bacterial in origin. Despite advances in therapy, it remains a medical emergency due to its potential for rapid deterioration and severe complications.

Meningitis occurs worldwide and can affect individuals of all ages, including previously healthy people. The overall incidence in the United States is approximately 2–10 cases per 100,000 population annually, with significantly higher rates in neonates and young children. Among bacterial causes, Neisseria meningitidis is unique in its ability to cause epidemics. Vaccination programs have significantly reduced cases of Haemophilus influenzae type B meningitis.
​
Risk factors include extremes of age, crowded living conditions, close contact with infected individuals, head trauma, neurosurgical devices (e.g., shunts), immunosuppression, and chronic illnesses. Specific conditions predispose to certain pathogens—for example, asplenia increases risk for pneumococcal and meningococcal infections, while complement deficiencies increase susceptibility to meningococcal disease. Tick exposure may lead to Lyme meningitis.

The pathogenesis begins with colonization of the nasopharynx, followed by invasion into the bloodstream and crossing of the blood–brain barrier into the cerebrospinal fluid (CSF), where pathogens multiply. Inflammation in the subarachnoid space leads to increased intracranial pressure and neurologic dysfunction.

Etiologically, most cases are viral, particularly due to enteroviruses. However, bacterial meningitis is more severe and commonly caused by Streptococcus pneumoniae, Neisseria meningitidis, Group B Streptococcus, Listeria monocytogenes, and Haemophilus influenzae. Other pathogens include viruses (e.g., herpesviruses, HIV), spirochetes such as Treponema pallidum, and Borrelia burgdorferi.

Clinically, patients often present with fever, headache, vomiting, and altered mental status. Classical meningeal signs include nuchal rigidity, Kernig’s sign, and Brudzinski’s sign, although these may not always be present. A petechial or purpuric rash suggests meningococcal infection. Severe cases may progress to seizures, coma, or focal neurologic deficits.

Presentation may be atypical in elderly patients and neonates.
Diagnosis requires urgent evaluation. Initial laboratory tests include blood work and cultures, followed by lumbar puncture to analyze CSF. In bacterial meningitis, CSF typically shows high white blood cell count with neutrophil predominance, low glucose, and elevated protein. In viral meningitis, lymphocytes predominate, and glucose is usually normal. PCR testing improves detection of both bacterial and viral pathogens. A CT scan of the head is indicated before lumbar puncture in patients with risk factors for increased intracranial pressure or focal neurologic signs.
​
Treatment must be initiated immediately, often before confirmation of the causative organism. Empiric therapy typically includes a third- or fourth-generation cephalosporin combined with vancomycin, with the addition of ampicillin when Listeria is suspected. Therapy is later tailored based on culture results. Adjunctive corticosteroids may be beneficial in certain cases, particularly pneumococcal meningitis, to reduce inflammation and neurologic complications.

All patients require hospitalization for close monitoring and supportive care. Prognosis depends on factors such as age, underlying health, pathogen, and timeliness of treatment. Mortality and morbidity increase with delayed therapy, altered consciousness, or severe disease at presentation.
​
Complications can be severe and include seizures, hydrocephalus, brain abscess, hearing loss, cognitive impairment, paralysis, and even death. Survivors often require long-term neurologic follow-up and rehabilitation.

​

Infectious Disease and Microbiology - Mediastinitis
Mediastinitis is a serious infection involving the mediastinum, the central compartment of the thoracic cavity. It may present as acute or chronic disease. Acute mediastinitis is a life-threatening condition often resulting from esophageal perforation, cardiothoracic surgery, trauma, or spread from nearby infections such as those of the head and neck. A particularly severe form is descending necrotizing mediastinitis, where infection spreads rapidly from the oropharynx into the chest. Chronic mediastinitis is less common and is typically associated with granulomatous diseases such as tuberculosis or histoplasmosis, or with retained foreign bodies.

Currently, most cases of mediastinitis occur as complications following cardiac surgery, especially after sternotomy. The incidence of post-surgical mediastinitis ranges from approximately 0.4% to 5%. Despite advances in surgical techniques and infection control, the incidence has remained stable due to increasing numbers of elderly and immunocompromised patients undergoing complex procedures. Risk factors include diabetes mellitus, obesity, chronic lung disease, prolonged surgical time, reoperation, and vascular comorbidities.

The pathophysiology involves invasion of the mediastinum by pathogens, leading to intense inflammation, fibrin deposition, and formation of abscesses. Infection can spread rapidly through fascial planes, creating extensive tissue damage and dead space beneath the sternum. Acute infections are usually polymicrobial. Common organisms include gram-positive bacteria such as Staphylococcus aureus and Staphylococcus epidermidis in post-surgical cases, while infections related to esophageal or oropharyngeal sources often involve gram-negative and anaerobic organisms. In severely ill patients, fungal pathogens like Candida and Aspergillus may also be involved.

Clinically, acute mediastinitis presents with fever, severe chest pain, dysphagia, and respiratory distress. Patients with esophageal perforation may also have epigastric pain. Physical findings can include a sternal click (indicating instability), crepitus due to subcutaneous air, and Hamman’s sign, a crunching sound heard over the chest. In contrast, chronic mediastinitis may initially be asymptomatic but later presents with symptoms due to compression of mediastinal structures, such as cough, dyspnea, or signs of superior vena cava syndrome.

Laboratory findings typically show leukocytosis and elevated inflammatory markers such as C-reactive protein. Blood cultures may be positive, especially in cases associated with head and neck infections. Imaging is essential for diagnosis. Chest radiographs may reveal mediastinal widening or air-fluid levels, while CT scans provide detailed visualization of fluid collections, gas, and the extent of infection. Diagnostic procedures such as CT-guided aspiration, mediastinoscopy, or thoracoscopy may be required to obtain microbiological samples.

Management of mediastinitis requires urgent and aggressive treatment. Broad-spectrum intravenous antibiotics should be initiated promptly and later tailored based on culture results. Common regimens include combinations of cephalosporins with anaerobic coverage or agents such as piperacillin-tazobactam. Coverage for MRSA may require vancomycin or linezolid. Therapy is typically prolonged, lasting several weeks.
Surgical intervention is critical and remains the cornerstone of treatment. Procedures include drainage of infected material, debridement of necrotic tissue, and sometimes more extensive approaches such as thoracotomy or video-assisted thoracic surgery. Negative pressure wound therapy may be used in postoperative cases. Supportive care, including airway management, oxygen therapy, and adequate nutrition, is essential.
​
The prognosis of mediastinitis is guarded, with mortality rates reaching up to 50%, especially in delayed or inadequately treated cases. Early diagnosis and prompt surgical drainage significantly improve outcomes. Complications can be severe and include sepsis, pleural empyema, sternal osteomyelitis, acute respiratory distress syndrome, thrombosis, and superior vena cava syndrome.

​